Compare WAVE & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAVE | PMCB |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3M | 5.3M |
| IPO Year | 2021 | N/A |
| Metric | WAVE | PMCB |
|---|---|---|
| Price | $6.21 | $0.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 12.6K | ★ 9.9M |
| Earning Date | 11-12-2025 | 12-15-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $168,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $400.00 | N/A |
| P/E Ratio | ★ N/A | $150.94 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.41 | $0.63 |
| 52 Week High | $17.38 | $1.90 |
| Indicator | WAVE | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 44.03 |
| Support Level | $6.39 | $0.82 |
| Resistance Level | $7.00 | $1.05 |
| Average True Range (ATR) | 0.31 | 0.18 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 11.54 | 15.73 |
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.